The clinical evidence
Selank's anxiety data are not imaginary. Russian trials compared it head to head with the benzodiazepines medazepam…
A real clinical record, in the wrong language
Selank's anxiety data are not imaginary. Russian trials compared it head to head with the benzodiazepines medazepam and phenazepam, and a later rodent paper summarizes them as showing comparable efficacy without the side effects typical of those drugs. The phenazepam trial, read in full, is more mixed than that summary. The catch is that these trials appear in Russian-language journals, and this course cites each through its English abstract.
This unit examines what the trials actually showed, why the language barrier is a real scientific limitation and not a footnote, and how to read this unusual evidence base honestly.
Key terms
The Zozulia comparison
The foundational clinical study compared Selank against the benzodiazepine medazepam in sixty-two patients with generalized anxiety disorder and neurasthenia (a condition the Russian label also lists among its indications), 30 on Selank and 32 on medazepam. The anxiolytic effects of both drugs were similar, but Selank added something medazepam lacked. Two details the abstract does not give: the route, and the treatment duration.
The headline is a genuine finding: in this trial, a peptide matched a benzodiazepine for anxiolytic effect while also showing antiasthenic and psychostimulant effects the comparator did not. Serum leu-enkephalin half-life rose alongside it, tying the clinical result loosely back to the mechanism. A later open Russian comparison against the benzodiazepine phenazepam in 60 patients with phobic-anxiety and somatoform disorders (Medvedev 2014) gives a more mixed picture. During the two weeks of treatment, phenazepam lowered anxiety scores further: by about a quarter on Selank against more than half on phenazepam. A week after stopping, Selank's effect had held and grown while phenazepam's faded, and Selank had more responders, seventeen against nine. Sedation, attention and memory complaints were common on phenazepam and essentially absent on Selank.
AdvancedWhat the enkephalin correlation does and does not show
A trial that only reports symptom scores can be hard to interpret, so a moving biomarker is welcome. Read this one exactly: the abstract reports that the increase in serum leu-enkephalin half-life, and stronger positive correlations with anxiety level, were seen during Selank treatment mostly in the GAD patients. It does not report a correlation with symptom change. So the biomarker moved and tracked how anxious patients were, which is weaker than a mechanism-to-response bridge and should not be described as one.